ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

Show other versions (1)
Bibliographic Details
Main Authors: A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920307252
id doaj-2695ce4f1444409bbb8802ec2b89a4c3
record_format Article
spelling doaj-2695ce4f1444409bbb8802ec2b89a4c32020-11-25T03:05:41ZengElsevierHematology, Transfusion and Cell Therapy2531-13792020-11-0142262263ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDYA. Maiolino0P. Moreau1M. Dimopoulos2J. Mikhael3K. Yong4M. Capra5T. Facon6R. Hajek7I. Spicka8M. Risse9G. Asset10S. Macé11T. Martin12Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, BrazilUniversity Hospital Hôtel-Dieu, Nantes, FranceThe National and Kapodistrian University of Athens, Athens, GreeceTranslational Genomics Research Institute, City of Hope Cancer Center, Phoenix, United StatesUniversity College Hospital, London, United KingdomHospital Mãe de Deus, Porto Alegre, RS, BrazilLille University Hospital, Lille, FranceUniversity Hospital Ostrava, Ostrava, Czech RepublicCharles University in Prague, Prague, Czech RepublicSanofi R&D, Vitry/Alfortville, FranceSanofi R&D, Chilly-Mazarin, FranceSanofi R&D, Vitry/Alfortville, FranceUniversity of California at San Francisco, San Francisco, United Stateshttp://www.sciencedirect.com/science/article/pii/S2531137920307252
collection DOAJ
language English
format Article
sources DOAJ
author A. Maiolino
P. Moreau
M. Dimopoulos
J. Mikhael
K. Yong
M. Capra
T. Facon
R. Hajek
I. Spicka
M. Risse
G. Asset
S. Macé
T. Martin
spellingShingle A. Maiolino
P. Moreau
M. Dimopoulos
J. Mikhael
K. Yong
M. Capra
T. Facon
R. Hajek
I. Spicka
M. Risse
G. Asset
S. Macé
T. Martin
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
Hematology, Transfusion and Cell Therapy
author_facet A. Maiolino
P. Moreau
M. Dimopoulos
J. Mikhael
K. Yong
M. Capra
T. Facon
R. Hajek
I. Spicka
M. Risse
G. Asset
S. Macé
T. Martin
author_sort A. Maiolino
title ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
title_short ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
title_full ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
title_fullStr ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
title_full_unstemmed ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
title_sort isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
publisher Elsevier
series Hematology, Transfusion and Cell Therapy
issn 2531-1379
publishDate 2020-11-01
url http://www.sciencedirect.com/science/article/pii/S2531137920307252
work_keys_str_mv AT amaiolino isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT pmoreau isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT mdimopoulos isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT jmikhael isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT kyong isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT mcapra isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT tfacon isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT rhajek isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT ispicka isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT mrisse isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT gasset isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT smace isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
AT tmartin isatuximabpluscarfilzomibanddexamethasonevscarfilzomibanddexamethasoneinrelapsedrefractorymultiplemyelomaikemainterimanalysisofaphase3randomizedopenlabelstudy
_version_ 1724677073530781696

Similar Items